News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Biosimilars will not deliver the same cost savings as generic drugs and may not even gain a strong foothold in the biologics market until 2019, according to a new report from GlobalData.
Increased regulatory expectation in the environmental monitoring of microbiological media has driven demand for prepared solutions, says Cherwell Laboratories as it completes a facility expansion.
German biopharmaceutical firm MorphoSys will collaborate with Merck Serono to develop antibodies for the latter’s immuno-oncology pipeline.
Small biotechs should consider buying mothballed plants when scaling-up according to Protein Sciences, which says an ex-Pfizer facility was key to accelerating production of its vaccine Flublok.